Stimvia wants to attract US investors to this round because it sees potential for expansion in the US market. Possible investors could include strategic players in neuromodulation therapy or large pharmacy chains. The company intends to launch this round by the end of the year and conclude it by mid-2025.

Stimvia, founded in 2014 by Lukáš Doskočil under the name Tesla Medical, emerged from the development phase of a project at the 2nd Medical Faculty of Charles University in Prague focused on the treatment of overactive bladder. The company has developed the URIS technology, which offers non-invasive stimulation of deep brain structures, protected by more than 100 patents worldwide. The URIS technology targets chronic diseases, including incontinence and Parkinson's disease, using electrical transcutaneous nerve modulation. Specialized electrodes enable precise stimulation of neural pathways and restore balance to brain activity.

The company is currently closing a $10 million Series A round of financing to establish an U.S. office with a management team. URIS has served approximately 500 patients in the Czech Republic and Slovakia to date.